Regulatory14 Jul 2026, 05:00 pm
IOL Chemicals gets China NMPA approval for Clopidogrel Bisulfate API
AI Summary
IOL Chemicals & Pharmaceuticals Ltd announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its API product, Clopidogrel Bisulfate. This approval, granted on July 14, 2026, is in addition to the company's existing Certificate of Suitability (CEP) for the same product. The NMPA approval is expected to significantly enhance the company's regulatory standing and expand its market access within China's pharmaceutical sector.
Key Highlights
- China's NMPA approves IOL Chemicals' Clopidogrel Bisulfate API.
- Approval strengthens regulatory portfolio and market access in China.
- Complements existing Certificate of Suitability (CEP).
- Enhances global pharmaceutical market presence.
- Dated July 14, 2026.
Price Impact
More from IOLCP